dapagliflozin
Farxiga
Pharmaceutical company: AstraZeneca
NEW INDICATION & DOSAGE
To reduce the risk of sustained eGFR decline, end-stage renal disease (ESRD), CV death, and hospitalization for heart failure in patients with chronic kidney disease at risk for progression
Adults: 10 mg PO once daily.
Adjust-a-dose: This drug is not recommended for initiation when eGFR is less than 25 mL/min/1.73 m2; however, patient may continue 10 mg PO once daily to reduce the risk of eGFR decline, ESRD, CV death, and hospitalization for heart failure.
CONTRAINDICATIONS & CAUTIONS
This drug is not recommended for treatment of chronic kidney disease in patients with polycystic kidney disease or those with current or recent immunosuppressive therapy for kidney disease.
Released: July 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
diclofenac potassium
Zipsor
Pharmaceutical company: Assertio Therapeutics, Inc.
NEW INDICATION & DOSAGE
Mild to moderate acute pain (Zipsor)
Adults and children age 12 and older: 25 mg PO q.i.d.
Released: July 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
nivolumab
Opdivo
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy
Adults: 240-mg IV infusion every 2 weeks, or 480-mg IV infusion every 4 weeks, until disease progression or unacceptable toxicity occurs, or up to 1 year of treatment.
Released: July 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
pembrolizumab
Keytruda
Pharmaceutical company: Merck Sharp & Dohme
NEW INDICATION & DOSAGE
First-line treatment in patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy
Adults: 200-mg IV infusion over 30 minutes every 3 weeks, or 400-mg IV infusion over 30 minutes every 6 weeks prior to trastuzumab and chemotherapy when given on the same day. Continue until disease progression or unacceptable toxicity occurs, or up to 24 months in those without disease progression.
Monotherapy treatment in patients with locally recurrent advanced or metastatic gastric or GEJ adenocarcinoma whose tumors express PD-L1 as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapy
Adults: 200-mg IV infusion over 30 minutes every 3 weeks, or 400-mg IV infusion over 30 minutes every 6 weeks until disease progression or unacceptable toxicity occurs, or up to 24 months in those without disease progression.
Released: July 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer
spinosad
Natroba
Pharmaceutical company: ParaPRO
NEW INDICATION & DOSAGE
Scabies infestation
Adults and children age 4 and older: Apply to skin to completely cover body from the neck to soles of feet. Patients with balding scalp should also apply to scalp, hairline, temples, and forehead. Allow skin to dry for 10 minutes before getting dressed. Leave on skin for 6 hours before showering or bathing.
Released: July 2021
Nursing Drug Handbook
© 2021 Wolters Kluwer